Skip To Main Content
Michael S. Saag on Muck Rack

Michael S. Saag

As seen in: The Washington Post, Washington Post Opinions, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, AL.com, Medscape, The New England Journal of Medicine, The Lancet, International Journal of Epidemiology, Annals of Internal Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael S.

Contact Michael S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Only you can save Birmingham’s medical rainforest: op-ed from UAB researcher

|
By Michael S. Saag
| AL.com Verified
This is a guest opinion column Academic Health Centers are like tropical rainforests: They take decades to develop and weeks to destroy. Birmingham’s very own medical rainforest—UAB—faces devastation from the “ONE BIG BEAUTIFUL BILL” being debated in the U.S. Senate. The bill proposes slashing National Institutes of Health (NIH) funding by 42%, from $47 billion to $29 billion annually, and cutting indirect cost recovery from 48.5% to 15%.
Open in Who Shared Issue with article?

Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel

|
By Paul E. Sax, Melanie Thompson, Michael S. Saag
| JAMA: Journal of the American Medical Association Verified
To the Editor Long-acting injectable cabotegravir and rilpivirine (CAB-RPV) is approved for people with HIV who have viral suppression with oral antiretroviral therapy (ART), no known or suspected resistance to either drug, and no chronic hepatitis B. In clinical trials, switching to this injectable therapy demonstrated noninferiority to continued oral ART in maintaining viral suppression.
Open in Who Shared Issue with article?

HIV and Antiretroviral Therapy Guidelines

|
By Michael S. Saag, Rajesh H Gandhi
| Medscape Verified
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael S. Saag, MD: Hello. I'm Dr Michael Saag, professor of medicine and infectious diseases at the University of Alabama at Birmingham. Welcome to season 2 of the Medscape InDiscussion Podcast series on HIV. Today we're going to discuss antiretroviral therapy (ART) guidelines. What's new in the field?
Open in Who Shared Issue with article?
See all 44 licensed articles (46 Total)